Published in Acta Neuropathol on March 22, 2009
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci (2011) 2.47
Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol (2014) 2.28
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
Does Alzheimer's disease begin in the brainstem? Neuropathol Appl Neurobiol (2009) 1.26
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol (2012) 1.04
Presenilins function in ER calcium leak and Alzheimer's disease pathogenesis. Cell Calcium (2011) 0.99
Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol (2012) 0.95
Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy. Neurology (2013) 0.94
The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology (2013) 0.92
Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis. J Clin Invest (2014) 0.88
Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol (2011) 0.86
Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis. US Neurol (2010) 0.86
BACE1 and presenilin/γ-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels. FASEB J (2013) 0.83
Age-related neurodegeneration and memory loss in down syndrome. Curr Gerontol Geriatr Res (2012) 0.83
Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations. J Alzheimers Dis (2013) 0.83
Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. J Biol Chem (2011) 0.81
Biological function of Presenilin and its role in AD pathogenesis. Transl Neurodegener (2013) 0.81
The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ. Acta Neuropathol Commun (2013) 0.80
Presenilin/gamma-Secretase and Inflammation. Front Aging Neurosci (2010) 0.79
Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation. Brain Pathol (2013) 0.78
Genetic Disorders with Tau Pathology: A Review of the Literature and Report of Two Patients with Tauopathy and Positive Family Histories. Neurodegener Dis (2015) 0.78
Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. Front Neurol (2015) 0.77
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement (2016) 0.75
Defining the earliest pathological changes of Alzheimer's disease. Curr Alzheimer Res (2016) 0.75
Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J Comp Neurol (2002) 1.58
P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol (2006) 1.43
The progression of pathology in Parkinson's disease. Ann N Y Acad Sci (2010) 1.21
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol (2009) 0.95
Variable phenotype of Alzheimer's disease with spastic paraparesis. J Neurochem (2007) 0.94
Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms. Exp Neurol (2007) 0.94
Working memory and schizophrenia: evidence for slowed encoding. Schizophr Res (2003) 0.94
LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models. J Mol Med (Berl) (2012) 0.88
Neurofilament-immunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiol Dis (2002) 0.88
No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov Disord (2009) 0.88
LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol (2008) 0.84
Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochim Biophys Acta (2010) 0.83
Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Expert Rev Neurother (2012) 0.82
Intraneuronal advanced glycation endproducts in presenilin-1 Alzheimer's disease. Neuroreport (2002) 0.81
Increased ATP-binding cassette transporter A1 expression in Alzheimer's disease hippocampal neurons. J Alzheimers Dis (2010) 0.81
Clinical correlates of similar pathologies in parkinsonian syndromes. Mov Disord (2011) 0.81
Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology. Brain (2010) 0.80
Unilateral rest tremor in vascular parkinsonism associated with a contralateral lesion of the locus coeruleus. Mov Disord (2009) 0.78
Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun (2013) 0.78